

(i)
(vi)
(v)
(ii)
(iii)
(iv)
pH-DEPENDENT BINDING ANTIBODY
SOLUBLE ANTIGEN
FcRn

Fig. 1



(i)
(ii)
(iii)
(iv)
(v)
(vi)
pH-DEPENDENT BINDING ANTIBODY
MEMBRANE-TYPE ANTIGEN
FcRn

Fig. 2




Fig. 3




Fig. 4






Fig. 5

(i)


RU
6RL#9
pH7.4, 2mM Ca
pH7.4, 3uM Ca
pH6.0, 2mM Ca
Normalized Response(Captured ligand=100 RU)
160
150
140
130
120
110
100
90
80
-50
0
50
100
150
200
250
300
Time

(ii)


RU
6RK#12
pH7.4, 2mM Ca
pH7.4, 3uM Ca
pH6.0, 2mM Ca
Normalized Response(Captured ligand=100 RU)
140
130
120
110
100
90
80
-50
0
50
100
150
200
250
300
Time

(iii)



RU
FH4
pH7.4, 2mM Ca
pH7.4, 3uM Ca
pH6.0, 2mM Ca
Normalized Response(Captured ligand=100 RU)
140
130
120
110
100
90
80
-50
0
50
100
150
200
250
300
Time

Fig. 6



RU
180
170
160
150
140
130
120
110
100
90
RESPONSE (0 = CAPTURE_BASELINE), (100 = CAPTURE_LEVEL_3)
39 nmol/L IL-6R (3 µM CaCl2)
39 nmol/L IL-6R (2 mM CaCl2)
BUFFER (2 mM CaCl2)
BUFFER (3 µM CaCl2)
-100 0 100 200 300 400 500 600 700 800 900 1000
TIME (0 = BASELINE)
S

Fig. 7



RU
180
170
160
150
140
130
120
110
100
90
RESPONSE (0 = CAPTURE_BASELINE), (100 = CAPTURE_LEVEL_3)
5 µmol/L IL-6R (2 mM CaCl2)
5 µmol/L IL-6R (3 µM CaCl2)
BUFFER (3 µM CaCl2)
BUFFER (2 mM CaCl2)
-100 0 100 200 300 400 500 600 700 800 900 1000
TIME (0 = BASELINE)
S

Fig. 8



RU
180
170
160
150
140
130
120
110
100
90
RESPONSE (0 = CAPTURE_BASELINE), (100 = CAPTURE_LEVEL_3)
5 µmol/L IL-6R (2 mM CaCl2)
5 µmol/L IL-6R (3 µM CaCl2)
BUFFER (3 µM CaCl2)
BUFFER (2 mM CaCl2)
-100 0 100 200 300 400 500 600 700 800 900 1000
TIME (0 = BASELINE)
S

Fig. 9



PLASMA ANTIBODY CONCENTRATION (μg/mL)
10000
1000
100
10
1
0
1
2
3
4
5
6
7
TIME (DAYS)
H54/L28-IgG1
6RL#9-IgG1
FH4-IgG

Fig. 10



PLASMA hsIL-6R CONCENTRATION (ng/mL)
10000
1000
100
10
1
0.0
0.5
1.0
1.5
2.0
TIME (DAYS)
6RL#9-IgG1
FH4-IgG1
hsIL-6R ALONE
H54/L28-IgG1

Fig. 11



1000
100
10
1
PLASMA ANTIBODY (μg/mL) CONCENTRATION
0
1
2
3
4
5
6
7
TIME (DAYS)
6RL#9-N434W
FH4-N434W
H54/L28-N434W

Fig. 12




10000
1000
100
10
1
PLASMA hsIL-6R CONCENTRATION (ng/mL)
0.0
0.5
1.0
1.5
2.0
TIME (DAYS)
6RL#9-N434W
FH4-N434W
hsIL-6R ALONE
H54/L28-N434W

Fig. 13

(i) CRYSTAL STRUCTURE IN THE PRESENCE OF CALCIUM ION



(ii) CRYSTAL STRUCTURE IN THE ABSENCE OF CALCIUM ION




Fig. 14



(i)
RU
6LC4-1#15
pH7.4, 1.2mM Ca
pH7.4, 3uM Ca
pH6.0, 1.2mM Ca
Normalized Response(Captured ligand=100 RU)
Time
(ii)
RU
6LC4-2#16
pH7.4, 1.2mM Ca
pH7.4, 3uM Ca
pH6.0, 1.2mM Ca
Normalized Response(Captured ligand=100 RU)
Time
(iii)
RU
6KC4-1#85
pH7.4, 1.2mM Ca
pH7.4, 3uM Ca
pH6.0, 1.2mM Ca
Normalized Response(Captured ligand=100 RU)
Time

Fig. 15



0.012
0.011
0.010
0.009
0.008
0.007
0.006
0.005
0.004
0.003
0.002
0.001
AU
10.00
12.00
14.00
16.00
18.00
20.00
22.00
24.00
26.00
28.00
30.00
32.00
34.00
MINUTE

FIG. 16




(i)LIGHT CHAIN:LfVk1_Ca
DEGRADATION PRODUCT
(ii)LIGHT CHAIN:LfVk1_Ca1
(iii)LIGHT CHAIN:LfVk1_Ca2
DEGRADATION PRODUCT
(iv)LIGHT CHAIN:LfVk1_Ca3
DEGRADATION PRODUCT
MINUTE
4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 20.00

FIG. 17

(i)LIGHT CHAIN:LfVk1_Ca



(ii)LIGHT CHAIN:LfVk1_Ca6






Fig. 18

(i)



(ii)



(iii)




Fig. 19



1000
100
10
1
PLASMA ANTIBODY CONCENTRATION
(μg/mL)
0
5
10
15
20
25
30
Time(day)
Q425-IgG1
Q425L9-IgG1
TNX355-IgG1

Fig. 20



100
10
1
0.1
PLASMA SOLUBLE HUMAN CD4 CONCENTRATION(μg/mL)
0
2
4
6
8
Time(day)
SOLUBLE HUMAN CD4
SOLUBLE HUMAN CD4+Q425-IgG1
SOLUBLE HUMAN CD4+Q425L9-IgG1
SOLUBLE HUMAN CD4+TNX355-IgG1

Fig. 21



(i)
RU
GA1-IgG1
Normalized Response(Capture ligand=100 RU)
Running Buffer
pH7.4, 1.2mM Ca
pH7.4, 3uM Ca
pH5.8, 1.2mM Ca
pH5.8, 3uM Ca
Time
s
(ii)
RU
GA2-IgG1
Normalized Response(Capture ligand=100 RU)
Running Buffer
pH7.4, 1.2mM Ca
pH7.4, 3uM Ca
pH5.8, 1.2mM Ca
pH5.8, 3uM Ca
Time
s
(iii)
RU
GA3-IgG1
Normalized Response(Capture ligand=100 RU)
Running Buffer
pH7.4, 1.2mM Ca
pH7.4, 3uM Ca
pH5.8, 1.2mM Ca
pH5.8, 3uM Ca
Time
s
(iv)
RU
GA4-IgG1
Normalized Response(Capture ligand=100 RU)
Running Buffer
pH7.4, 1.2mM Ca
pH7.4, 3uM Ca
pH5.8, 1.2mM Ca
pH5.8, 3uM Ca
Time
s

Fig. 22



10000.0
1000.0
100.0
10.0
1.0
PLASMA ANTIBODY CONCENTRATION(μg/mL)
0
2
4
6
8
TIME (DAYS)
(2)IgA+GA1-IgG1
(3)IgA+GA2-IgG1
(4)IgA+GA3-IgG1
(4)IgA+GA2-N434W

Fig. 23



100
10
1
0.1
0.01
PLASMA HUMAN IgA CONCENTRATION(μg/mL)
0
2
4
6
8
TIME (DAYS)
(1) IgA ALONE
(2) IgA+GA1-IgG1
(3) IgA+GA2-IgG1
(4) IgA+GA3-IgG1
(5) IgA+GA2-N434W

Fig. 24



0.30
0.25
0.20
0.15
0.10
0.05
0.00
UNBOUND HUMAN IgA CONCENTRATION(μg/mL)
0
2
4
6
8
TIME (DAYS)
(2) IgA+GA1-IgG1
(3) IgA+GA2-IgG1
(4) IgA+GA3-IgG1
(4) IgA+GA2-N434W

Fig. 25



IN PLASMA
(EXTRACELLULAR)
BIND TO A RECEPTOR (FcRn,
FcgR, COMPLEMENT RECEPTOR)
CELL SURFACE
DEGRADATION
BIND TO ENDOSOME
LYSOSOME

Fig. 26



IN PLASMA
(EXTRACELLULAR)
BIND TO A RECEPTOR
(FcRn, FcgR, COMPLEMENT
RECEPTOR)
CELL SURFACE
BIND TO FcRn AND
TRANSFER TO
EXTRACELLULAR
ANTIBODY
ANTIBODY
DISSOCIATES
FROM ANTIGEN
DEGRADATION
LYSOSOME
ENDOSOME

Fig. 27



IN PLASMA
(EXTRACELLULAR)
BIND TO A RECEPTOR
(FcRn, FcgR, COMPLEMENT
RECEPTOR)
CELL SURFACE
BIND TO FcRn AND
TRANSFER TO
EXTRACELLULAR
ANTIBODY
ANTIBODY
DISSOCIATES
FROM ANTIGEN
ENDOSOME
DEGRADATION
LYSOSOME

Fig. 28



(i) CSCM-01_005
ABSORBANCE 450nm
0.6
0.5
0.4
0.3
0.2
0.1
0
0.1
1
10
ANTIBODY CONCENTRATION(μg/mL)
1.2mM Ca(pH7.4)
3μM Ca(pH7.4)
1.2mM Ca(pH5.8)
3μM Ca(pH5.8)
(ii) CSCM-01_009
ABSORBANCE 450nm
0.5
0.4
0.3
0.2
0.1
0
0.1
1
10
ANTIBODY CONCENTRATION(μg/mL)
1.2mM Ca(pH7.4)
3μM Ca(pH7.4)
1.2mM Ca(pH5.8)
3μM Ca(pH5.8)
(iii) CSCM-01_015
ABSORBANCE 450nm
0.5
0.4
0.3
0.2
0.1
0
0.1
1
10
ANTIBODY CONCENTRATION(μg/mL)
1.2mM Ca(pH7.4)
3μM Ca(pH7.4)
1.2mM Ca(pH5.8)
3μM Ca(pH5.8)
(iv) CSCM-01_023
ABSORBANCE 450nm
0.6
0.5
0.4
0.3
0.2
0.1
0
0.1
1
10
ANTIBODY CONCENTRATION(μg/mL)
1.2mM Ca(pH7.4)
3μM Ca(pH7.4)
1.2mM Ca(pH5.8)
3μM Ca(pH5.8)
(v) GC-IgG1
ABSORBANCE 450nm
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.1
1
10
ANTIBODY CONCENTRATION(μg/mL)
1.2mM Ca(pH7.4)
3μM Ca(pH7.4)
1.2mM Ca(pH5.8)
3μM Ca(pH5.8)

Fig. 29



2mM Ca2+
3 μ M Ca2+
2.5
2
1.5
1
0.5
0
ABSORBANCE(OD405nm)
GEB0100
GEB0220
GEB0230
Xolair

FIG. 30



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1
-v2
hsIL-6R+H54/L28
-IgG1
100000
10000
1000
100
10
PLASMA ANTIBODY CONCENTRATION(ng/mL)
0
1
2
3
4
5
6
7
TIME (DAYS)

FIG. 31



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1 -v2
hsIL-6R+H54/L28 -IgG1
hsIL-6R
10000
1000
100
10
1
0 1 2 3 4 5 6 7
TIME (DAYS)
SOLUBLE HUMAN IL-6 RECEPTOR CONCENTRATION IN PLASMA (ng/mL)

FIG. 32



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1 -v2
hsIL-6R+Fv4-IgG1 -v1
hsIL-6R+H54/L28 -IgG1
100000
10000
1000
100
10
0
1
2
3
4
5
6
7
TIME (DAYS)
PLASMA ANTIBODY CONCENTRATION (ng/mL)

FIG. 33



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1 -v2
hsIL-6R+Fv4-IgG1 -v1
hsIL-6R+H54/L28 -IgG1
hsIL-6R
10000
1000
100
10
1
0
1
2
3
4
5
6
7
TIME (DAYS)
SOLUBLE HUMAN IL-6 RECEPTOR CONCENTRATION IN PLASMA (ng/mL)

FIG. 34



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1 -v2
hsIL-6R+Fv4-IgG1 -v1
hsIL-6R+H54/L28
-IgG1
25
20
15
10
5
0
0
1
2
3
4
5
6
7
TIME (DAYS)
CONCENTRATION OF UNBOUND SOLUBLE HUMAN IL-6 RECEPTOR (ng/mL)

FIG. 35



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1-v2
hsIL-6R+Fv4-IgG1-F14
hsIL-6R+Fv4-IgG1-F20
hsIL-6R+Fv4-IgG1-F21
hsIL-6R+Fv4-IgG1-F25
hsIL-6R+Fv4-IgG1-F29
hsIL-6R+Fv4-IgG1-F35
hsIL-6R+Fv4-IgG1-F48
hsIL-6R+Fv4-IgG1-F93
hsIL-6R+Fv4-IgG1-F94
hsIL-6R
10000
1000
100
10
1
0
1
2
3
4
TIME (DAYS)
PLASMA CONCENTRATION OF SOLUBLE HUMAN IL-6 RECEPTOR (ng/mL)

FIG. 36



hsIL-6R+Fv4-IgG1(1mg/kg)
hsIL-6R+Fv4-IgG1-F14(1mg/kg)
hsIL-6R+Fv4-IgG1-F14(0.01mg/kg)
hsIL-6R
PLASMA CONCENTRATION OF SOLUBLE HUMAN IL-6 RECEPTOR (ng/mL)
10000
1000
100
10
1
0
1
2
3
4
TIME (DAYS)

FIG. 37



hsIL-6R+Fv4-IgG1(1mg/kg)
hsIL-6R+Fv4-IgG1-F14(1mg/kg)
hsIL-6R+Fv4-IgG1-F14(0.01mg/kg)
PLASMA ANTIBODY CONCENTRATION
(ng/mL)
100000
10000
1000
100
10
1
0
1
2
3
4
TIME (DAYS)

FIG. 38



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1-v2
hsIL-6R+Fv4-IgG1-F20
hsIL-6R+H54/L28-IgG1
hsIL-6R
1000
100
10
1
0
5
10
15
20
TIME (DAYS)
PLASMA CONCENTRATION OF SOLUBLE HUMAN IL-6 RECEPTOR (ng/mL)

FIG. 39



hsIL-6R+Fv4-M73
hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1-v2
hsIL-6R+Fv4-IgG1-v1
hsIL-6R+H54/L28-IgG1
100
10
1
0.1
0
7
14
21
TIME (DAYS)
PLASMA ANTIBODY CONCENTRATION
(μg/mL)

FIG. 40



hsIL-6R+Fv4-M73
hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1-v2
hsIL-6R+Fv4-IgG1-v1
hsIL-6R+H54/L28-IgG1
hIL-6R
10000
1000
100
10
1
0
5
10
15
20
25
TIME (DAYS)
PLASMA hsIL-6R CONCENTRATION
(ng/mL)

FIG. 41



Fv4-IgG1
Fv4-M73
Fv4-IgG1-v1
Fv4-IgG1-v2
Fv4-IgG1-F14
Fv4-IgG1-F20
Fv4-IgG1-F29
Fv4-IgG1-F35
Fv4-IgG1-F48
Fv4-IgG1-F93
Fv4-IgG1-F94
FITTING CURVE
1000
100
10
1
1.0E-03
1.0E-04
1.0E-05
1.0E-06
1.0E-07
1.0E-08
1.0E-09
2.3μM
PLASMA hsIL-6R CONCENTRATION
1 DAY AFTER ADMINISTRATION(ng/mL)
KD AT pH 7.0 (M)

FIG. 42



◆ Fv4-IgG1
□ Fv4-M73
× Fv4-IgG1-v1
■ Fv4-IgG1-v2
▲ Fv4-IgG1-F14
◇ Fv4-IgG1-F20
● Fv4-IgG1-F21
⊿ Fv4-IgG1-F25
✳ Fv4-IgG1-F29
○ Fv4-IgG1-F35
+ Fv4-IgG1-F48
△ Fv4-IgG1-F93
– Fv4-IgG1-F94
100
10
1
0.1
PLASMA ANTIBODY CONCENTRATION
1 DAY AFTER ADMINISTRATION
(μg/mL)
0.2 μM
1.0E-03
1.0E-04
1.0E-05
1.0E-06
1.0E-07
1.0E-08
1.0E-09
KD AT pH 7.0 (M)

FIG. 43



Fv4-IgG1
Fv4-M73
Fv4-IgG1-v1
Fv4-IgG1-v2
Fv4-IgG1-F14
Fv4-IgG1-F20
Fv4-IgG1-F21
Fv4-IgG1-F25
Fv4-IgG1-F29
Fv4-IgG1-F35
Fv4-IgG1-F48
Fv4-IgG1-F93
Fv4-IgG1-F94
1
0.1
0.01
0.001
0
1
2
3
4
TIME (DAYS)
ANTIGEN/ANTIBODY MOLAR RATIO (C VALUE)

FIG. 44



Fv4-IgG1
Fv4-M73
Fv4-IgG1-v1
Fv4-IgG1-v2
Fv4-IgG1-F14
Fv4-IgG1-F20
Fv4-IgG1-F21
Fv4-IgG1-F25
Fv4-IgG1-F29
Fv4-IgG1-F35
Fv4-IgG1-F48
Fv4-IgG1-F93
Fv4-IgG1-F94
FITTING CURVE
1
0.1
0.01
0.001
1.0E-03
1.0E-04
1.0E-05
1.0E-06
1.0E-07
1.0E-08
1.0E-09
3.0 μM
KD AT pH 7.0 (M)
ANTIGEN/ANTIBODY MOLAR RATIO (C VALUE)

FIG. 45



hsIL-6R+Fv4-IgG1 (1 mg/kg)
hsIL-6R+Fv4-IgG1-F14 (1 mg/kg)
hsIL-6R+Fv4-IgG1-F14 (0.2 mg/kg)
hsIL-6R+Fv4-IgG1-F14 (0.01 mg/kg)
hsIL-6R
← DETECTION LIMIT
100
10
1.56
0
7
14
TIME (DAYS)
PLASMA hsIL-6R CONCENTRATION(ng/mL)

FIG. 46



hsIL-6R+Fv4-IgG1 (LINEAGE276)
hsIL-6R+Fv4-IgG1 (LINEAGE32)
hsIL-6R+Fv4-IgG1-v2 (LINEAGE276)
hsIL-6R+Fv4-IgG1-v2 (LINEAGE32)
hsIL-6R+H54/L28-IgG1 (LINEAGE276)
hsIL-6R+H54/L28-IgG1 (LINEAGE32)
PLASMA hsIL-6R CONCENTRATION (ng/mL)
10000
1000
100
10
1
0
1
2
3
4
TIME (DAYS)

FIG. 47



hsIL-6R+Fv4-IgG1 (LINEAGE276)
hsIL-6R+Fv4-IgG1 (LINEAGE32)
hsIL-6R+Fv4-IgG1-v2 (LINEAGE276)
hsIL-6R+Fv4-IgG1-v2 (LINEAGE32)
hsIL-6R+H54/L28-IgG1 (LINEAGE276)
hsIL-6R+H54/L28-IgG1 (LINEAGE32)
100
10
1
0.1
0
1
2
3
4
TIME (DAYS)
PLASMA ANTIBODY CONCENTRATION(μg/mL)

FIG. 48



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1-F11
hsIL-6R+Fv4-IgG1-F14
hsIL-6R+Fv4-IgG1-F39
hsIL-6R+Fv4-IgG1-F48
hsIL-6R+Fv4-IgG1-F140
hsIL-6R+Fv4-IgG1-F157
hsIL-6R+Fv4-IgG1-F194
hsIL-6R+Fv4-IgG1-F196
hsIL-6R+Fv4-IgG1-F198
hsIL-6R+Fv4-IgG1-F262
hsIL-6R+Fv4-IgG1-F264
hsIL-6R+Fv4-IgG1-F393
hsIL-6R+Fv4-IgG1-F424
hsIL-6R+Fv4-IgG1-F447
hsIL-6R
DETECTION LIMIT
100
10
1.56
0
7
14
TIME (DAYS)
PLASMA hsIL-6R CONCENTRATION(ng/mL)

FIG. 49



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1-F11
hsIL-6R+Fv4-IgG1-F14
hsIL-6R+Fv4-IgG1-F39
hsIL-6R+Fv4-IgG1-F48
hsIL-6R+Fv4-IgG1-F140
hsIL-6R+Fv4-IgG1-F157
hsIL-6R+Fv4-IgG1-F194
hsIL-6R+Fv4-IgG1-F196
hsIL-6R+Fv4-IgG1-F198
hsIL-6R+Fv4-IgG1-F262
hsIL-6R+Fv4-IgG1-F264
hsIL-6R+Fv4-IgG1-F393
hsIL-6R+Fv4-IgG1-F424
hsIL-6R+Fv4-IgG1-F447
100
10
1
0.1
0.01
0
7
14
TIME (DAYS)
PLASMA ANTIBODY CONCENTRATION(μg/mL)

FIG. 50



Fv4-IgG1
Fv4-IgG1-F11
Fv4-IgG1-F14
Fv4-IgG1-F39
Fv4-IgG1-F48
Fv4-IgG1-F140
Fv4-IgG1-F157
Fv4-IgG1-F194
Fv4-IgG1-F196
Fv4-IgG1-F198
Fv4-IgG1-F262
Fv4-IgG1-F264
Fv4-IgG1-F393
Fv4-IgG1-F424
Fv4-IgG1-F447
1
0.1
0.01
0.001
0
7
14
TIME (DAYS)
ANTIGEN/ANTIBODY MOLAR RATIO (C VALUE)

FIG. 51



● hsIL-6R+Fv4-IgG1
△ hsIL-6R+Fv4-IgG1-F11
✕ hsIL-6R+Fv4-IgG1-F14
▲ hsIL-6R+Fv4-IgG1-F39
◆ hsIL-6R+Fv4-IgG1-F48
▨ hsIL-6R+Fv4-IgG1-F140
■ hsIL-6R+Fv4-IgG1-F157
□ hsIL-6R+Fv4-IgG1-F194
○ hsIL-6R+Fv4-IgG1-F196
× hsIL-6R+Fv4-IgG1-F198
◇ hsIL-6R+Fv4-IgG1-F262
◬ hsIL-6R+Fv4-IgG1-F264
◍ hsIL-6R+Fv4-IgG1-F393
◈ hsIL-6R+Fv4-IgG1-F424
⊸ hsIL-6R+Fv4-IgG1-F447
0.1
0.01
0.001
1.0E-03
1.0E-04
1.0E-05
1.0E-06
1.0E-07
1.0E-08
KD AT pH 7.0 (M)
ANTIGEN/ANTIBODY MOLAR RATIO (C VALUE)

FIG. 52



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1-F11
hsIL-6R+Fv4-IgG1-F39
hsIL-6R+Fv4-IgG1-F48
hsIL-6R+Fv4-IgG1-F264
PLASMA ANTIBODY CONCENTRATION(μg/mL)
100
10
1
0.1
0.01
0
7
14
TIME (DAYS)

FIG. 53



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1-F11
hsIL-6R+Fv4-IgG1-F39
hsIL-6R+Fv4-IgG1-F48
hsIL-6R+Fv4-IgG1-F264
hsIL-6R
100
10
1
0
7
14
TIME (DAYS)
PLASMA hsIL-6R CONCENTRATION(ng/mL)

FIG. 54



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1-F157
hsIL-6R+Fv4-IgG1-F196
hsIL-6R+Fv4-IgG1-F262
100
10
1
0.1
0.01
0
7
14
21
28
TIME (DAYS)
PLASMA ANTIBODY CONCENTRATION(μg/mL)

FIG. 55



hsIL-6R+Fv4-IgG1
hsIL-6R+Fv4-IgG1-F157
hsIL-6R+Fv4-IgG1-F196
hsIL-6R+Fv4-IgG1-F262
DETECTION LIMIT
100
10
1.56
0
7
14
21
28
TIME (DAYS)
PLASMA hsIL-6R CONCENTRATION(ng/mL)

FIG.56